BioLife Solutions Inc (BLFS) fair value: what the stock is really worth
As of Oct 7, 2026: fair value (intrinsic value) of BioLife Solutions Inc stock $4.46, price $38.61, upside -88.4%, quality 56 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.
How to read this chart
60‑month range $8.99 – $60.50 · fair‑value band $2.95 – $6.74 · the $38.61 price screens above the $4.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.
Follow BioLife Solutions in your weekly email
Every Wednesday you see whether BioLife Solutions is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
Show moreShow less
The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors.
The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Stock analysis
BioLife Solutions Inc (BLFS) currently trades at $38.61, while our model-based Fair Value estimate is $4.46, 88.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $4.71 per share, and 0 of the 10 models we run sit above the $38.61 price.
Bear case: the Multiples group reads lowest at $1.34, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: $2.95 (bear) to $6.74 (bull), the price of $38.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BioLife Solutions Inc reported revenue of $96.2M in FY2025 versus $119M in FY2021, a compound −5.2%/yr. Reported net income was −$12.1M in FY2025.
Key figures
Market cap $1.9B Small · P/E ratio 39.0 · P/S ratio 17.8 · EPS (TTM) $0.9900 · Net margin 54.4% · Return on equity 12.8% · Return on assets (EBIT) −3.1% · Operating margin 6.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 113% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at −88%, BLFS screens richer than that median.
Fair Value models
Bear$2.95Fair Value $4.46Bull$6.74
Price $38.61 · Upside -88.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.8191 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.91/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+17.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.9%
Start year 2020 (pandemic). Over 10 years: +31.0% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.9% (2020) → −1.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+65.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+14.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +61.6% a year for the price and +12.1% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 185 stocks
Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score56 · Below median
Fair Value upside−88.4% · Bottom 25%
Profitability
Return on equity (12 months)12.8% · Above median
Return on assets−3.0% · Bottom 25%
Net margin (12 months)54.4% · Top 25%
Operating margin (12 months)6.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)21.5% · Top 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)39.0× · Pricier than median
P/B5.12× · Priciest 25%
P/S (12 months)17.84× · Priciest 25%
Price / free cash flow178.9× · Priciest 25%
PEG65.38× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)100· sector 40
PAST (return on equity)51· sector 30
HEALTH (low debt)99· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BioLife Solutions Inc (BLFS) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of $4.46 versus the last price from Oct 7, 2026 of $38.61, about −88% upside (overvalued).
What is the fair value of BLFS?
Our model-based fair value for BioLife Solutions Inc is $4.46 (as of Oct 29, 2026), built from audited fundamentals. Last price (from Oct 7, 2026): $38.61.
What is the quality score of BLFS?
BioLife Solutions Inc has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioLife Solutions Inc (BLFS)?
Our model-based price target is the fair value of $4.46 (as of Oct 29, 2026) from 10 valuation models. Cautious scenario $2.95, optimistic scenario $6.74. It is a calculation from audited fundamentals, not an analyst target.
What is the BioLife Solutions Inc stock forecast for 2026?
Our models put fair value at $4.46, about −88% upside versus the last price from Oct 7, 2026 of $38.61 (overvalued). Cautious scenario $2.95, optimistic scenario $6.74. The calculation is refreshed regularly with new filings.
What is the revenue of BioLife Solutions Inc (BLFS)?
BioLife Solutions Inc reported trailing-twelve-month revenue of about $107M (latest available figure, as of Oct 29, 2026).
What growth is priced into BioLife Solutions Inc (BLFS)?
For today's price to be fair in a discounted-cash-flow model, BioLife Solutions Inc would have to grow free cash flow by +65.5 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.9 % per year. As of Oct 29, 2026.
What discount rate (WACC) does the fair value of BLFS use?
Our models discount BioLife Solutions Inc at 13.5 %: a base by market capitalisation (small), damped by beta 1.82, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BioLife Solutions Inc that is +65.5 % per year a year over ten years, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has BioLife Solutions Inc (BLFS) delivered so far?
Over the past 5 years revenue at BioLife Solutions Inc grew +14.9 % a year. The price currently implies +65.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BioLife Solutions Inc (BLFS) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into BioLife Solutions Inc (+65.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BioLife Solutions Inc (BLFS)?
The free-cash-flow yield on the price is 0.56 %: that much free cash flow BioLife Solutions Inc produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BioLife Solutions Inc (BLFS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioLife Solutions Inc it is $4.46 per share (as of Oct 29, 2026), against a price of $38.61. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is BioLife Solutions Inc stock overvalued or undervalued in 2026?
As of Oct 29, 2026, BLFS trades above its calculated fair value: price $38.61, fair value $4.46, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BLFS?
No. The price is what the market pays today ($38.61); the fair value is what the company's own numbers justify ($4.46). For BioLife Solutions Inc the two are $34.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioLife Solutions Inc worth?
The market values BioLife Solutions Inc at about $1.9B (market capitalisation, as of Oct 29, 2026). Per share that is $38.61; our models calculate a fair value of $4.46 per share.
What do the bullish and bearish scenarios say about BLFS?
Our models span a range for BioLife Solutions Inc: cautious scenario $2.95, base $4.46, optimistic $6.74 per share (as of Oct 29, 2026, price $38.61). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BLFS?
BioLife Solutions Inc trades at a price-to-earnings ratio of 39.0 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.46 is built from several models across several years. Other multiples: PEG 65.4, P/B 5.1, P/S 17.8.
What is the PEG ratio of BLFS?
The PEG ratio of BioLife Solutions Inc is 65.38 (P/E divided by earnings growth, as of Oct 29, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of BioLife Solutions Inc (BLFS)?
Balance-sheet figures for BioLife Solutions Inc (as of Oct 29, 2026): return on equity 12.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is BLFS from its 52-week high?
BioLife Solutions Inc trades at $38.61, about 2% below its 52-week high of $39.22 and 113% above the low of $18.15 (as of Oct 7, 2026). Distance from the high says nothing about value: that is what the fair value of $4.46 is for.
Which stocks are comparable to BioLife Solutions Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioLife Solutions Inc stock attractive at the current price?
The data as of Oct 29, 2026: price $38.61, calculated fair value $4.46 (−88%), Quality Score 56/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BLFS calculated?
We run BioLife Solutions Inc through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.46, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. BioLife Solutions Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioLife Solutions Inc (BLFS)?
The latest price we hold is from Oct 7, 2026 and stands at $38.61. Our model-based fair value is $4.46, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioLife Solutions Inc right now?
The price sits above even our optimistic bull case ($6.74). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($2.95 to $6.74) leaves room in how you read the outcome.
Key figures of BioLife Solutions Inc
How large is the market capitalisation of BioLife Solutions Inc (BLFS)?
The market capitalisation of BioLife Solutions Inc is $1.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioLife Solutions Inc (BLFS)?
The price-to-sales ratio of BioLife Solutions Inc is 17.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioLife Solutions Inc (BLFS)?
Earnings per share at BioLife Solutions Inc are $0.9900 (price ÷ EPS = P/E 39.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BioLife Solutions Inc (BLFS)?
The net margin of BioLife Solutions Inc is 54.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioLife Solutions Inc (BLFS)?
The return on equity (ROE) of BioLife Solutions Inc is 12.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioLife Solutions Inc (BLFS)?
On an EBIT basis the return on assets of BioLife Solutions Inc is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioLife Solutions Inc (BLFS)?
The operating margin of BioLife Solutions Inc is 6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioLife Solutions Inc (BLFS)?
Revenue at BioLife Solutions Inc is growing +21.5% versus a year earlier (3y avg +8.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioLife Solutions Inc (BLFS)?
Earnings per share at BioLife Solutions Inc are growing −13.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does BioLife Solutions Inc (BLFS) hold?
BioLife Solutions Inc holds more cash than debt, $15.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch BioLife Solutions Inc in the live analysis
One click puts BioLife Solutions Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 29, 2026